Antihypertensive Effects of Mibefradil in the Treatment of Mild-to-Moderate Systemic Hypertension
Open Access
- 1 August 1997
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 80 (4) , 12C-19C
- https://doi.org/10.1016/s0002-9149(97)00565-1
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Antihypertensive Properties of the Novel Calcium Antagonist Mibefradil (Ro 40-5967)Hypertension, 1996
- Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom populationBMJ, 1995
- Current status of calcium channel blockersCurrent Problems in Cardiology, 1994
- Selective inhibition of T-type Ca2+ channels by Ro 40-5967.Circulation Research, 1994
- Cardiovascular Profile of Ro 40–5967, a New Nondihydropyridine Calcium Antagonist, Delineated in Isolated, Blood-Perfused Dog HeartsJournal of Cardiovascular Pharmacology, 1993
- Lack of Negative Inotropic Effects of the New Calcium Antagonist Ro 40–5967 in Patients with Stable Angina PectorisJournal of Cardiovascular Pharmacology, 1991
- Ro 40–5967: A New Nondihydropyridine Calcium AntagonistCardiovascular Drug Reviews, 1991
- The structurally novel Ca2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat heartsCardiovascular Drugs and Therapy, 1990
- Calcium Entry Blockers in the Treatment of HypertensionPublished by American Medical Association (AMA) ,1989
- In Vitro Pharmacologic Profile of Ro 40-5967, a Novel Ca2+ Channel Blocker with Potent Vasodilator but Weak Inotropic ActionJournal of Cardiovascular Pharmacology, 1989